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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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Low concordance of multiple variant-calling
pipelines: practical implications for exome and
genome sequencing
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Hakon Hakonarson6, W Evan Johnson7, Zhi Wei4, Kai Wang8,9* and Gholson J Lyon1,2,9*
Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
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•  “If	  you	  want	  something	  hard,	  try	  clinical	  
medicine”	  -­‐	  Bruce	  Korf	  
yet	  
•  “proprietary	  databases”	  =	  “walled	  gardens”	  
	  

Biometry	  
MutaKon	  ≠	  Phenotype	  
•  Ancestry	  maIers!	  
•  Context	  maIers!	  
•  Other	  mutaKons	  maIer!	  
•  Environment	  maIers!	  
•  Longitudinal	  course	  maIers!	  

Categorical	  Thinking	  Misses	  Complexity	  
Expression	  Issues	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  	  preIy	  much	  
ALL	  mutaKons	  in	  humans,	  as	  we	  have	  not	  
systemaKcally	  sequenced	  or	  karyotyped	  any	  geneKc	  
alteraKon	  in	  Thousands	  to	  Millions	  of	  randomly	  
selected	  people,	  nor	  categorized	  into	  ethnic	  classes,	  
i.e.	  clans.	  
•  There	  is	  a	  MAJOR	  clash	  of	  world-­‐views,	  i.e.	  do	  single	  
mutaKons	  drive	  outcome	  predominately,	  or	  are	  the	  
results	  modiﬁed	  substanKally	  by	  geneKc	  background	  
and/or	  environment?	  i.e.	  is	  there	  really	  such	  a	  thing	  as	  
geneKc	  determinism	  for	  MANY	  mutaKons?	  
Vigne@e	  #1:	  One	  person	  with	  very	  severe	  obsessive	  
compulsive	  disorder,	  severe	  depression	  and	  
intermi@ent	  psychoses	  
	  
40	  year	  old	  Caucasian	  man	  from	  Utah	  

Nucleus	  accumbens	  
Fig.	  1.	  Coronal	  secKon	  of	  the	  brain	  near	  the	  nucleus	  accumbens	  with	  the	  track	  of	  
the	  electrodes	  on	  the	  le`	  and	  right	  side.	  
	  
Two	  year	  follow-­‐up	  
Figure 2.   Yale Brown Obsessive Compulsive Scale (YBOCS) scores were measured 
for M.A  over a three year and seven months period of time.  A time series plot (A) 
shows a steady decline in YBOCS scores over the period of time spanning his DBS surgery 
(s) and treatment.   Incremental adjustments to neurostimulator voltage are plotted over a 
period of time following DBS surgery (A).  Mean YBOCS scores are plotted for sets of 
measurements taken before and after his Deep Brain Stimulation (DBS) surgery (B).  A 
one-tailed  unpaired  t  test  with  Welch’s  correction  results  in  a  p  value  of 
0.0056,  demonstrating  a significant difference  between YBOCS scores measured before 
and after the time of surgery.	
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain ﬁndings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
speciﬁc variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular ﬁndings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneﬁcial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactly con-
stitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or is
it the entire process from sample receipt through to the generation
and return of a report? Here, the legal deﬁnition is really quite
clear, as CLIA speciﬁcally states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performsnonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are speciﬁ-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difﬁculties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation of
NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through th tate following s ccessful state certiﬁ-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptabl
numbers of sp cimens for valid tion studies and guideli es for
stablishi g read dep , accuracy, sensitivity, tc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is deﬁned by both the sequencing
and downstream informatics, and the informatics possibilities for a
standar equence are essentially limitless, how could CLIA supervi-
sion be applied to combined research and clinical genomics operations
without placi g an extreme regu atory burden on the sequencing
laboratory? Would every analysis type need to be certiﬁed, or would
a time-consuming standardized analysis be required even if it were
not needed for each p rticular peration?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The beneﬁts of enacting such a split model could be substantial,
and we believe they could be gained without signiﬁcantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually
Table 1
Processes involved in a CLIA-certiﬁed genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure m nual
2) Test systems, equipment, instrum nts, reagents, mat rials and
supplies
3) Establishment and veriﬁcation of performance speciﬁcations
4) Maintenance and function checks
5) Calibration and calibration veriﬁcation procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
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1.	  Sample	  CollecKon	  and	  handling	  
	  
	  
2.	  Sequencing/AnalyKcs	  
	  
	  
3.	  InterpretaKon	  
“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characterisKcs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cerKﬁed,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  AdministraKon.	  If	  you	  have	  
any	  quesKons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informaKon,	  you	  should	  contact	  your	  doctor	  or	  a	  geneKc	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	  
Sample	  CollecKon	  and	  Handling	  	  
The	  Sample	  CollecKon	  kit	  includes	  barcoded	  collecKon	  tubes,	  a	  
Test	  RequisiKon	  form,	  an	  Informed	  PaKent	  Consent	  form,	  and	  a	  pre-­‐paid	  
shipping	  envelope.	  All	  paperwork	  must	  be	  completed	  and	  returned	  for	  
sample	  processing.	  Requests	  for	  Sample	  CollecKon	  kits	  must	  be	  
submiIed	  by	  a	  physician.	  
hIp://www.illumina.com/clinical/illumina_clinical_laboratory/igs_for_doctors/
how_to_order.ilmn	  
	  
Sequencing	  and	  AnalyKcs	  


Table 1.  A summary of three clinically relevant genetic aberrations found in the clinical sequencing results of M.A.  
Mutations in MTHFR, BDNF,  and ChAT were found to be of potential clinical relevance for this person, as they are all implicated in 
contributing to the susceptibility and development of many neuropsychiatric disorders that resemble those present within M.A.  A 
brief summary of the characteristics of each mutation is shown, including the gene name, genomic coordinates, amino acid change, 
zygosity, mutation type, estimated population frequency and putative clinical significance. 
 
Gene name Genomic coordinates Amino acid change Zygosity Mutation type Population Frequency Clinical significance 
MTHFR chr1: 11854476 Glu>Ala heterozygous non-synon T:77% G:23% 
Susceptibility to psychoses, 
schizophrenia, occlusive vascular 
disease, neural tube defects, 
colon cancer, acute leukemia, and 
methylenetetra-hydrofolate 
reductase deficiency  
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% 
Susceptibility to OCD, psychosis, 
and diminished response to 
exposure therapy  
CHAT chr10: 50824117 Asp>Asn heterozygous non-synon G:85% A:15% 
Susceptibility to schizophrenia and 
other psychopathological 
disorders. 
   
3	  common	  SNVs	   n	  this	  person	  that	  have	  been	  impl cated	  in	  the	  
literature	  as	  predisposing	  to	  mental	  illness.	  

Lessons	  
  Should	  look	  at	  enKre	  genome.	  
  Should	  archive	  and	  store	  genomic	  data	  for	  re-­‐
analysis	  for	  many	  years	  to	  come.	  
	  
VigneIe	  #2:	  New	  Syndrome	  with	  
Intellectual	  Disability,	  “AuKsm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  RetardaKon	  
“auKsm”	  
“ADHD”	  
Hearing	  diﬃculKes	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  geneKc	  tests	  negaKve,	  including	  
negaKve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
•  Whole genome sequencing was performed 
using : 
–  Complete Genomics sequencing and analysis 
pipeline v2.0 
–  llumina HiSeq 2000 sequencing platform.  
•  Illumina reads were mapped to the hg19 reference 
genome using BWA v. 0.6.2-r126 
•  Variant detection was performed using the GATK v. 
2.4-9.   
•  A second analytical pipeline was used to map reads to 
the hg19 reference genome using Novoalign, and 
variants were also detected using the FreeBayes caller. 
•  For each sequenced individual, a union of the 
calls made by both sequencing platforms, as 
well as all bioinformatics analysis platforms, 
was taken.   
•  Standard approaches can then be used to 
identify potentially deleterious mutations 
conforming to classical disease models for 
genetic disorders.   
 
•  We subset the full dataset to evaluate 
differences between raw numbers of 
mutations detected between different data 
sets:  
–  WGS data from the nuclear family,  
–  WGS from a larger portion of the family.	  
Using only nuclear family: 
55195 Variants were found to be de-novo in the two affected boys  
122 were coding : 
107 non-synonymous missense 
4 splicing  
3 frame-shift deletions 
3 frame-shift insertions 
2 frame-shift substitutions 
2 stop-gain  
1 stop-loss 
26514 Variants were found to conform to an X-linked disease model 
28 were coding: 
27 non-synonymous missense 
1 splicing 
Using information from a greater portion of the family structure: 
17726 Variants were found to be de-novo in the two affected boys  
40 were coding : 
32 non-synonymous missense 
3 splicing  
2 frame-shift deletions 
1 stop-loss 
1 frame-shift insertion 
1 frame-shift substitution 
2824 Variants were found to conform to an X-linked disease model 
4 were coding: 
3 non-synonymous missense 
1 splicing 
•  The	  numbers	  of	  mutaKons	  diﬀer	  as	  expected	  
between	  these	  two	  sets	  of	  analyses:	  	  
	  
– More	  mutaKons	  are	  ﬁltered	  when	  a	  greater	  
porKon	  of	  the	  family	  is	  incorporated	  into	  the	  
analysis.	  	  	  
	  
– This	  is	  likely	  due	  to	  false	  posiKve	  and	  false	  
negaKve	  rates	  across	  sequencing	  and	  informaKcs	  
plakorms.	  
Using only nuclear family: 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF4 0.00192 0.00144,0.00265 13.13 chr1:12939476;13.13;G->C;N->K;0,1 
2 PRAMEF10 0.00318 0.00243,0.00417 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
3 LOC440563 0.00523 0.00416,0.00653 9.89 chr1:13183056;9.89;T->C;N->D;0,1 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 ASB12 0.000898 0.000898,0.00119 18.7 chrX:63444792;18.70;C->A;G->C;0,1 
2 TAF1 0.00153 0.00117,0.00214 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
3 ZNF41 0.002 0.0015,0.00275 12.9 chrX:47307978;12.90;G->T;D->E;0,1 
Using information from a greater  
portion of the family structure: 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF10 0.00342 0.00262,0.00445 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 TAF1 0.002 0.0015,0.00275 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
The	  two	  brothers	  with	  the	  P111L	  
mutaKons	  reported	  in	  the	  prior	  
paper	  do	  have	  mental	  deﬁciency,	  
hyperkinesia,	  no	  motor	  or	  
neurologic	  sign	  except	  for	  the	  
delay,	  and	  slight	  dysmorphic	  facial	  
anomalies:	  large	  low-­‐set	  ears,	  thin	  
upper	  lip,	  slight	  downward	  
palpebral	  slants,	  but	  no	  upturned	  
nose,	  and	  a	  short	  philtrum.	  The	  
mother	  was	  normal	  in	  appearance.	  	  
•  Previously	  reported	  P111L	  change	  in	  the	  
ZNF41	  protein	  has	  now	  also	  been	  found	  in	  two	  
"male	  controls"	  (EVS	  server,	  ESP6500),	  and	  
furthermore,	  there	  are	  two	  rare,	  likely	  
heterozygous	  ZNF41	  frameshi`	  mutaKons	  and	  
one	  heterozygous	  stop-­‐gained	  mutaKon	  
reported	  in	  control	  individuals	  (ESP6500)	  
(personal	  communicaKon	  from	  Dr.	  Vera	  
Kalscheuer).	  	  
Major	  Conclusion:	  Clinical	  Validity?	  
	  
This	  is	  so	  complex	  that	  the	  only	  solid	  way	  
forward	  is	  with	  a	  “networking	  of	  science”	  
model,	  i.e.	  online	  database	  with	  genotype	  
and	  phenotype	  longitudinally	  tracked	  for	  
thousands	  of	  volunteer	  families.	  
	  
We	  need	  a	  1	  Million	  Genome/
Phenome	  Project!	  
 Creating a Global Alliance to 
Enable Responsible Sharing 
of Genomic and Clinical Data 
June 3, 2013 
An initial draft of this White Paper was prepared for the January 28th meeting, and  
has since been revised substantially based on discussions at and since the meeting. 
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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
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Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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electronically published November 18, 2003.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.

•  Whole genome sequencing was performed 
using : 
–  Complete Genomics sequencing and analysis 
pipeline v2.0 
–  llumina HiSeq 2000 sequencing platform.  
•  Illumina reads were mapped to the hg19 reference 
genome using BWA v. 0.6.2-r126 
•  Variant detection was performed using the GATK v. 
2.4-9.   
•  A second analytical pipeline was used to map reads to 
the hg19 reference genome using Novoalign, and 
variants were also detected using the FreeBayes caller. 
•  For each sequenced individual, a union of the 
calls made by both sequencing platforms, as 
well as all bioinformatics analysis platforms, 
was taken.   
•  Standard approaches can then be used to 
identify potentially deleterious mutations 
conforming to classical disease models for 
genetic disorders.   
 
•  We subset the full dataset to evaluate 
differences between raw numbers of 
mutations detected between different data 
sets:  
–  WGS data from the nuclear family,  
–  WGS from a larger portion of the family.	  
Using only nuclear family: 
55195 Variants were found to be de-novo and shared in the two 
affected boys  
122 were coding : 
107 non-synonymous missense 
4 splicing  
3 frame-shift deletions 
3 frame-shift insertions 
2 frame-shift substitutions 
2 stop-gain  
1 stop-loss 
26514 Variants were found to conform to an X-linked disease model 
28 were coding: 
27 non-synonymous missense 
1 splicing 

•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcripKon	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcripKonal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interacKon	  module	  
which	  represses	  transcripKon	  through	  recruiKng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochromaKn	  protein	  1	  (HP1)	  family,	  and	  other	  chromaKn	  
modulaKng	  proteins,	  leading	  to	  transcripKonal	  repression	  
through	  heterochromaKn	  formaKon.	  
ZNF41	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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  Causality	  
•  Will	  need	  to	  ﬁnd	  a	  second,	  unrelated	  family	  with	  same	  exact	  mu aKon	  and	  
similar	  phenotype.	  
•  Can	  also	  p rform	  in	  vitro/in	  vivo	  studies	  an 	  struct ral	  mod ling,	  and	  make	  
knock-­‐in	  mice	  and/or	  test	  in	  zebraﬁsh,	  etc…	  for	  biological	  funcKon.	  
Nuclear family, using only Illumina data 
50715 Variants were found to be de-novo in the two affected boys  
107 were coding : 
 
                  2 frame-shift substitutions 94 non-synonymous missense 
                  2 frame-shift deletions 4 splicing  
                  3 frame-shift insertions 2 stop-gain  
25157 Variants were found to conform to an X-linked disease model 
29 were coding: 
 
                  1 frame-shift deletions 28 non-synonymous missense 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF4 0.00216 0.00162,0.00294 13.13 chr1:12939476;13.13;G->C;N->K;0,1 
2 LOC440563 0.00538 0.00429,0.00671 9.89 chr1:13183056;9.89;T->C;N->D;0,1 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 ASB12 0.000898 0.000898,0.00119 18.7 chrX:63444792;18.70;C->A;G->C;0,1 
2 VCX3A 0.00145 0.00112,0.00203 13 chrX:6451809;13.00;T->C;M->V;0,1 
3	   TAF1	   0.00169	   0.00128,0.00235	   14.59	   chrX:70621541;14.59;T-­‐>C;I-­‐>T;0,1	  
4	   ZNF41	   0.00231	   0.00174,0.00314	   12.9	   chrX:47307978;12.90;G-­‐>T;D-­‐>E;0,1	  
Nuclear family, using only CG data 
42072 Variants were found to be de-novo in the two affected boys  
75 were coding : 
 
                     3 frame-shift deletions 62 non-synonymous missense 
                     4 frame-shift insertions 5 splicing  
1 stop-loss  
21397 Variants were found to conform to an X-linked disease model 
25 were coding: 
 
                     1 splicing 24 non-synonymous missense 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF10 0.00318 0.00243,0.00417 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 ASB12 0.000898 0.000898,0.00119 18.7 chrX:63444792;18.70;C->A;G->C;0,1 
2 TAF1 0.00145 0.00112,0.00203 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
3	   ZNF41	   0.00271	   0.00205,0.00361	   12.9	   chrX:47307978;12.90;G-­‐>T;D-­‐>E;0,1	  
A greater portion of the family, using only Illumina data 
11675 Variants were found to be de-novo in the two affected boys  
18 were coding : 
                          15 non-synonymous missense 
                           2 splicing 
                           1 frame-shift substitution 
1773 Variants were found to conform to an X-linked disease model 
3 were coding: 
                           3 non-synonymous missense 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
- - - - - - 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 TAF1 0.00184 0.00139,0.00255 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
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The duplication architecture of the human genome predisposes our species to recurrent copy number
variation and disease. Emerging data suggest that this mechanism of mutation contributes to both
common and rare diseases. Two features regarding this form of mutation have emerged. First, common
structural polymorphisms create susceptible and protective chromosomal architectures. These structural
polymorphisms occur at varying frequencies in populations, leading to different susceptibility and ethnic
predilection. Second, a subset of rearrangements shows extreme variability in expressivity. We propose
that two types of genomic disorders may be distinguished: syndromic forms where the phenotypic features
are largely invariant and those where the same molecular lesion associates with a diverse set of diagnoses
including epilepsy, schizophrenia, autism, intellectual disability and congenital malformations. Copy number
variation analyses of patient genomes reveal that disease type and severity may be explained by the occur-
rence of additional rare events and their inheritance within families. We propose that the overall burden of
copy number variants creates differing sensitized backgrounds during development leading to different
thresholds and disease outcomes. We suggest that the accumulation of multiple high-penetrant alleles
of low frequency may serve as a more general model for complex genetic diseases, posing a significant
challenge for diagnostics and disease management.
INTRODUCTION
Genomic disorders were originally described as large deletions
and duplications that are highly penetrant, mostly de novo in
origin, and typically identified in affected individuals with intel-
lectual disability/multiple congenital malformations. Some
examples include Smith–Magenis syndrome (MIM: 182290),
DiGeorge/velocardiofacial syndrome (MIM: 188400, 192430)
andWilliams–Beuren syndrome (MIM: 194050). These classi-
cal genomic disorders have been well characterized in the past
two decades with genotype–phenotype correlation studies
implicating causative genes, mouse models recapitulating the
human clinical features, and standardized management proto-
cols and support groups established.
Application of higher definition molecular techniques,
including single-nucleotide polymorphism microarrays or
array comparative genomic hybridization (CGH), has allowed
genotyping of larger disease cohorts and controls. Two major
principles have emerged from these more recent studies: (i)
common copy number polymorphism predisposes certain
chromosomes to recurrent deletions and duplications and
(ii) association of the same recurrent genomic lesion with
apparently very diverse phenotypes. The latter has begun to
illuminate common neurodevelopmental pathways and
helps to explain the comorbidity of diverse neurological
manifestations within the same families. The distinction
between variability of expressivity and reduced penetrance
depending on the diagnosis has become an important consider-
ation for these rare mutational events. We will explore the
mechanisms, models and implications underlying these two
different aspects.
GENOMIC SUSCEPTIBILITY TO RECURRENT
DELETIONS AND DUPLICATIONS
Seminal work on Charcot–Marie–Tooth disease (1,2) and
hereditary neuropathy with liability to pressure palsies
(HNPP) (3) directly implicated low-copy repeats or segmental
duplications as substrates for unequal crossover or non-allelic
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Objective: The authors used a genome-
wide association study (GWAS) of multiply
affected families to investigate the associ-
ation of schizophrenia to common single-
nucleotide polymorphisms (SNPs) and rare
copy number variants (CNVs).
Method: The family sample included
2,461 individuals from 631 pedigrees (581
in the primary European-ancestry analyses).
Association was tested for single SNPs and
genetic pathways. Polygenic scores based
on family study results were used to predict
case-control status in the Schizophrenia
Psychiatric GWAS Consortium (PGC) data
set, and consistency of direction of effect
with the family study was determined for
top SNPs in the PGC GWAS analysis. Within-
family segregation was examined for
schizophrenia- ss ciated rare CNVs.
Results: No genome-wide signiﬁcant asso-
ciationswereobserved for single SNPs or for
pathways. PGC case and control subjects
had signiﬁcantly different genome-wide
polygenic scores (computed by weighting
their genotypes by log-odds ratios from the
family study) (best p=10217, explaining
0.4% of the variance). Family study and
PGC analyses had consistent directions for
37 of the 58 independent best PGC SNPs
(p=0.024). The overall frequency of CNVs
in regions with reported associations
with schizophrenia (chromosomes 1q21.1,
15q13.3, 16p11.2, and 22q11.2 and the
neurexin-1 gene [NRXN1]) was similar to
previou case-control studies. NRXN1
deletions and 16p11.2 duplications (both
of which were transmitted from parents)
and 22q11.2 deletions (de novo in four
cases) did not segregate with schizophre-
nia in families.
Conclusions: Many common SNPs are
likely to contribute to schizophrenia risk,
with substantial overlap in genetic risk
factors between multiply affected families
and ses in l rge case-control st dies. Our
ﬁndings are consistentwith a role for speciﬁc
CNVs in disease pathogenesis, but the partial
segregationof someCNVswith schizophrenia
suggests that researchers should exercise
caution in using them for predictive genetic
testing until their effects in diverse popula-
tions have been fully studied.
Am J Psychiatry Levinson et al.; AiA:1–11
We report here on the ﬁrst genome-wide associ-
ation study (GWAS) in families with multiple members
with schizophrenia. Signiﬁcant associations of single-
nucleotide polymorphisms (SNPs) can suggest new
disease susceptibility mechanisms. For schizophrenia,
large GWAS analyses of common SNPs have found
associations in the major histocompatibility complex
(MHC, chromosome 6) (1–3) and several speciﬁc genes
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“Rare	  CNVs	  wer 	   bserve 	  in	  regions	  with	   trong	  previ u ly	   cum n ed	  associaKon	  
with	  schizophrenia,	  but	  with	  variable	  paIerns	  of	  segregaKon.	  This	  should	  serve	  as	  a	  
reminder	  that	  we	  sKll	  know	  relaKvely	  liIle	  about	  the	  distribuKon	  of	  these	  CNVs	  in	  the	  
enKre	  populaKon	  (e.g.,	  in	  individuals	  with	  no	  or	  only	  mild	  cog iKve	  problems)	  or	  about	  
the	  reas ns	   or	  the	  emerg nce	   f	  sc izophrenia	  in	  only	  a	   inority	   f	  c rriers,	  so	  great	  
cauKon	  is	  required	  in	  geneKc	  counseling	  and	  prediagnosis.”	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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
Applied & Translational Genomics xxx (2013) xxx–xxx
Abbreviations: CLIA, Clinical Laboratory Improvements Amendments; NGS, Next
generation sequencing; WGS, whole-genome sequencing.
⁎ Correspondence to: G.J. Lyon, Stanley Institute for Cognitive Genomics, Cold Spring
Harbor Laboratory, NY, United States. Tel.: +1 1446468721219.
⁎⁎ Correspondence to: J.P. Segal, New York Genome Center, New York, NY. Tel.: +1
888 415 6942.
E-mail addresses: GholsonJLyon@gmail.com (G.J. Lyon), jeremypsegal@gmail.com
(J.P. Segal).
ATG-00009; No of Pages 7
2212-0661/$ – see front matter © 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.atg.2013.02.001
Contents lists available at SciVerse ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atg
Please cite this article as: Lyon, G.J., Segal, J.P., Practical, ethical and regulatory considerations for the evolving medical and research genomics
landscape, Applied & Translational Genomics (2013), http://dx.doi.org/10.1016/j.atg.2013.02.001
2	  mutaKons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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SIFT	  classiﬁcaKon	  
Variant	  classiﬁcaKon	  
VAAST	  score	  
Chromosome	   PosiKon	   Reference	   Coding?	   SIFT	  Score	   Score	  <=	  0.05	   Ref/Alt	  Alleles	  
X	   47307978	   G	   YES	   0.649999976	   0	   G/T	  
X	   63444792	   C	   YES	   0	   1	   C/A	  
X	   70621541	   T	   YES	   0.009999999776	   1	   T/C	  
Variant	   Reference	   Alternate	   ClassiﬁcaKon	   Gene	  1	   Transcript	  1	   Exon	  1	   HGVS	  Coding	  1	   HGVS	  Protein	  1	  
X:47307978-­‐SNV	   G	   T	   Nonsyn	  SNV	   ZNF41	   NM_007130	   5	  c.1191C>A	   p.Asp397Glu	  
X:63444792-­‐SNV	   C	   A	   Nonsyn	  SNV	   ASB12	   NM_130388	   2	  c.739G>T	   p.Gly247Cys	  
X:70621541-­‐SNV	   T	   C	   Nonsyn	  SNV	   TAF1	   NM_004606	   25	  c.4010T>C	   p.Ile1337Thr	  
RANK	   Gene	   p-­‐value	   p-­‐value-­‐ci	   Score	   Variants	  
1	   ASB12	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   38.63056297	   chrX:63444792;38.63;C-­‐>A;G-­‐>C;0,3	  
2	   TAF1	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   34.51696816	   chrX:70621541;34.52;T-­‐>C;I-­‐>T;0,3	  
3	   ZNF41	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   32.83011803	   chrX:47307978;32.83;G-­‐>T;D-­‐>E;0,3	  
